

CLINICAL AND EXPERIMENTAL VACCINE RESEARCH

Clin Exp Vaccine Res 2012;1:83-87
<http://dx.doi.org/10.7774/cevr.2012.1.1.83>
 pISSN 2287-3651 • eISSN 2287-366X

Pil-Gu Park^{1*}, Min-Hee Cho^{1*},
 Gi-eun Rhie¹, Haeseul Jeong¹,
 Hyewon Youn^{2,3}, Kee-Jong Hong¹

¹Division of High-Risk Pathogen Research, Center for Infectious Diseases, Korea National Institute of Health, Cheongwon; ²Laboratory of Molecular Imaging and Therapy, Cancer Research Institute, Seoul National University College of Medicine, Seoul; ³Department of Nuclear Medicine, Cancer Imaging Center, Seoul National University Hospital, Seoul, Korea

Received: May 15, 2012
 Revised: June 5, 2012
 Accepted: June 10, 2012

Corresponding author: Kee-Jong Hong, PhD
 Division of High-Risk Pathogen Research,
 Center for Infectious Diseases, Korea National
 Institute of Health, Osong Health Technology
 Administration Complex, 187 Osongsaengmyeong
 2-ro, Osong-eup, Cheongwon 363-951, Korea
 Tel: +82-43-719-8271, Fax: +82-43-719-8309
 E-mail: khong@nih.go.kr

*Both authors equally contributed to this research.

No potential conflict of interest relevant to this article was reported.

This study was supported by Korea National Institute of Health (grant number 2011-N45003-00).



© Korean Vaccine Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

GFP-tagged *E. coli* shows bacterial distribution in mouse organs: pathogen tracking using fluorescence signal

Purpose: In vaccine efficacy evaluation, visualization of pathogens in whole organism at each time point would be able to reduce the consuming animals and provide the *in vivo* information within consistent background with identical organism.

Materials and Methods: Using IVIS spectrum whole live-animal imaging system, fluorescent intensity was optimized and visualized proportionately by concentrating *Escherichia coli* MC1061 strain which expresses GFP (*E. coli*-GFP) in BALB/C mice after injection.

Results: Local distribution of disseminated *E. coli*-GFP was traced in each organ by fluorescence. Detached organ showed more obvious fluorescent signal, and intestine showed strongest fluorescent signal.

Conclusion: This *in vivo* imaging method using GFP-tagged pathogen strain suggest quantified infected pathogens by fluorescence intensity in whole animals can provide the information about the localization and distribution after infection.

Keywords: Molecular imaging, GFP-tagged, Bacterial infections, Pathogen tracking, *Escherichia coli*

Introduction

Biology is an integrated study, which aimed to discover the various mechanisms in complex network. Although conventional experiments based on biochemical experiment can suggest 'clue' of individual mechanism in certain condition, but they restricted to reveal the 'real' phenomenon in whole cell or organism level. Molecular imaging is a powerful tool to discover various biological mechanisms, providing temporal and spatial information of cell and organism level [1,2]. The spatio-temporal analysis could provide the more exact mechanism in complex and changeable system, living organism. As researches become more complex with our knowledge of biological system, the role of molecular imaging are more increasing.

Infectious disease is one of the required fields with molecular imaging. Infection is complex process in whole organism related with various molecules in pathogens and host. As the biological effects of pathogen and immunological responses of host are varies at each time course and each organ [3], study of infectious disease requires analysis with various conditions. In conventional analysis with animal experiment as host system, enormous labor, time and animals are needed with long time-consuming experiment at separated time point. But, molecular imaging analysis which can chase

the pathogens in organism level, pathogen can overcome the limitation of conventional analysis and biological and pathological process and be monitored. In recent study, it was discovered that bubonic plague is colonized at lymph node first, and disseminated at liver and spleen by visualization of bioluminescence *Yersinia pestis* [4]. In similar analysis system, the primary germination site of *Bacillus anthracis* spore in organism was revealed as lung [5].

Vaccine is one of the ideal solutions against infectious disease. In order to develop efficient vaccine, efficacy evaluation methods with high accuracy are required. In conventional method for efficacy evaluation of vaccine have been dependent on detection of immunoglobulin for specific antigens or observation of animal lethality [3,6]. But, the former cannot provide direct efficacy against disease, the latter requires a lot of labors and animals. In vaccine efficacy evaluation, visualization of pathogens in whole organism at each time point would be able to reduce the consuming animals and provide the *in vivo* information within consistent background with identical organism.

In this study, we verified the application of *in vivo* molecular imaging system as vaccine efficacy evaluation method using fluorescent *Escherichia coli*, and suggest that the possibility of novel method for vaccine evaluation system.

Materials and Methods

Bacterial strain and growth condition

E. coli-green fluorescent protein (*E. coli*-GFP) strain MC1061 with GFP expression plasmid obtained from Korea National Institute of Health (KNIH; Osong, Korea). *E. coli*-GFP was cultured in Luria Bertani broth (Invitrogen, Carlsbad, CA, USA) in 37°C. One hundred µg/mL ampicillin (Invitrogen) was used as antibiotics to selection of bacteria containing GFP expression plasmid.

Measurement of bacteria density and relative fluorescence intensity

Bacteria density was determined by measurement of OD⁶⁰⁰ and calculated with matched bacteria density—OD⁶⁰⁰ index. Relative fluorescence intensity of *E. coli*-GFP was measured using SpectraMax (Molecular Devices, Sunnyvale, CA, USA) with 485 nm of excitation and 510 nm of emission filters [7,8].

Whole-animal fluorescent imaging

Five to six weeks old of female BALB/c mice were purchased

and used in bacteria injection experiment. All experiments were accomplished under the provision of KNIH Institutional Animal Care and Use Committee. *E. coli*-GFP was injected with intradermal (i.d.) of intraperitoneal (i.p.) route to BALB/c mice and injected mice were analyzed with IVIS spectrum whole live-animal imaging system (Perkin Elmer Inc., Waltham, MA, USA). Mice were anesthetized with isoflurane using a vaporizer, and fluorescent image was obtained GFP filter set (excitation wave length, 488 nm; emission wave length, 510 nm).

Results

Fluorescent signal was increased by bacterial replication

Compared to wild type *E. coli* strain, fluorescent intensity was increased proportionately by concentrating *E. coli* MC1061 strain which expresses GFP (*E. coli*-GFP), which suggest quantified fluorescent intensity can indicate the number of bacteria (Table 1, Fig. 1A). Fluorescent signal of *E. coli*-GFP was visualized by IVIS spectrum analysis and signal intensity could be represented by pseudo-color distribution (Table 1, Fig. 1B). Increasing of fluorescent signals was matched with the number of bacteria measured by optical density at 600 nm.

Injected bacteria was traced by fluorescent signal on the molecular imaging system

Visualizing of bacteria which reside inside of whole animal is most essential factor for *in vivo* live imaging. After confirmation of fluorescent signal increased by bacterial replication, GFP-tagged strain was injected at different colony-forming unit (CFU) through the various routes and the fluorescent signal was measured. To verify the possibility of applying fluorescence expressing pathogen to *in vivo* monitoring system of pathogen infection, we injected *E. coli*-GFP to mice with i.d. and i.p. route (Fig. 2). Over 10⁹ CFU, injected *E. coli*-GFP in both cases was clearly visualized in IVIS analysis system,

Table 1. Concentration of diluted *E. coli*-GFP for optimizing bacterial counts

Well no.	CFU (no. of bacteria)
1	2.0×10 ⁹
2	1.0×10 ⁹
3	5.0×10 ⁸
4	2.5×10 ⁸
5	1.2×10 ⁸

E. coli-GFP, *Escherichia coli* MC1061 strain which expresses green fluorescent protein; CFU, colony-forming unit.




Fig. 1. Fluorescent signal of *E. coli*-GFP strain. (A) Relative fluorescence intensity of *E. coli*-GFP. Fluorescent signal intensity was increased by bacteria count. Intensity of highly concentrated bacteria (No. 1) appeared as saturated signal. Bacteria numbers matched with each number (1-5) are presented at Table 1. (B) Visualization of serial diluted *E. coli*-GFP. In pseudo-color covered image, the high intensity of fluorescence appeared as red color and low intensity of fluorescence as blue. *E. coli*-GFP, *Escherichia coli* MC1061 strain which expresses green fluorescent protein.




Fig. 2. Visualization of *E. coli*-GFP strain in mice by *in vivo* imaging. (A) Fluorescent imaging of *E. coli*-GFP injected with intradermal route. 5×10^9 CFU (500 μ L) of *E. coli*-GFP was subcutaneously injected and dorsal side of mice were analyzed. Left animal, injected mouse; right animal, uninjected mouse; pseudo-color, red (high) to blue (low). (B) Fluorescent imaging of *E. coli*-GFP injected with intraperitoneal route. 3.5×10^9 CFU (350 μ L) of *E. coli*-GFP was injected to abdominal cavity and ventral side of injected mice were analyzed. Left animal, injected mouse; right animal, uninjected mouse; pseudo-color, blue (high) to red (low). *E. coli*-GFP, *Escherichia coli* MC1061 strain which expresses green fluorescent protein; CFU, colony-forming unit.

suggesting fluorescent signal can be pass through skin of animal and be detected. Although auto-fluorescent signal from naïve animal was strong, high intensity of fluorescent signal from *E. coli*-GFP was distinguishable and can be normalized with background signal.

Visualizing disseminated pathogen showed different signals in each organ

Infected pathogen can disseminated to several organs in animal, and targeting of pathogen toward specific organ is related with pathogenic disease. So, investigation of disseminated localization of pathogen is important to study of disease and




Fig. 3. Visualization of *E. coli*-GFP strain in mice by anatomical imaging. (A) Fluorescent imaging of *E. coli*-GFP injected to each organ. Mouse was administered euthanasia and opened the chest and abdominal cavity for direct injection of bacteria. $0.5\text{--}1.0 \times 10^9$ CFU of *E. coli*-GFP was injected to each organ. (B) Fluorescent imaging of detached organ of (A). Left lung was not injected with bacteria. Pseudo-color, blue (high) to red (low). *E. coli*-GFP, *Escherichia coli* MC1061 strain which expresses green fluorescent protein; CFU, colony-forming unit.

also evaluation of vaccine efficacy. In anatomical condition, each organ which directly injected with *E. coli*-GFP was visualized by IVIS analysis system (Fig. 3A). Detached organ showed more obvious fluorescent signal, and intestine showed strongest fluorescent signal (Fig. 3B). This seems to be due to its cavity structure that could contain bacteria. Organ of infectious situation, which provide the condition of bacterial infiltration to cells of organ, would be represented with more obvious and strong signal.

Discussion

Vaccine efficacy is usually tested using IgG titer after vaccination or protection assay with animals. Of course those methods are very effective to confirm the efficacy and safety for newly developed vaccine candidates and currently available vaccines on the improvement. However we still can't get further information about the distribution and clearance of infected pathogens after vaccination. To fill the gap of information about the works of vaccines, *in vivo* imaging using GFP-conjugated pathogens can be applied for pathogen trac-

ing and immune cell trafficking.

Injected bacteria was clearly distinguished organ by organ presumably representing bacterial replication levels or integrated bacterial number in each organ (Fig. 3). It was clear that fluorescence-tagged bacterial strain was replicated both on the culture plates and in the animals (Figs. 1, 3), however, *in vivo* tracing was not completely possible only with fluorescence-tagging on the current *in vivo* imaging apparatus due to the penetration capacity of fluorescence and the intensity of current fluorescence-tagging molecules [9].

There are several limits to use the GFP-conjugated bacteria to trace the pathogen distribution and clearance. First of all, GFP signals are usually not strong enough to be analyzed on currently available *in vivo* imaging systems, luciferase or other stronger signals could be considered for better signal tracing for infected pathogens [10,11]. Even though autofluorescence from animal body itself can be normalized using imaging software, still fluorescence signal seems not enough to show the track and localization of infected bacteria or other pathogens in each organ. Second, the sensitivity of fluorescence is not high enough to detect small number of infected

pathogens, especially for chronic infection diseases without exponential replication such as acquired immunodeficiency syndrome or tuberculosis. Visualization of signal-tagged pathogens can be traced and measured after several multiplications in animal body, but the quick multiplication of infected pathogens cannot be expected in chronic infectious diseases. This low multiplicity of infection in chronic infection could be another limit for pathogen tracing in infected animals.

Even though these several limits, the visualizing methods using signal-tagged pathogens can be a good model system to enforce the efficacy tests of vaccines or new drug candidates because it can supply related information about the pathogen localization and distribution after infection, also about the pathogen clearance in each targeted organ [12-15]. With more strong visualizing signals such as luciferase or optical nanomolecules, the molecular imaging methods for pathogen tracing and clearance could be a highly confident way to evaluate the vaccine efficacy in the future.

References

1. Golovliov I, Baranov V, Krocova Z, Kovarova H, Sjostedt A. An attenuated strain of the facultative intracellular bacterium *Francisella tularensis* can escape the phagosome of monocytic cells. *Infect Immun* 2003;71:5940-50.
2. Doyle TC, Burns SM, Contag CH. In vivo bioluminescence imaging for integrated studies of infection. *Cell Microbiol* 2004;6:303-17.
3. Shen H, Harris G, Chen W, Sjostedt A, Ryden P, Conlan W. Molecular immune responses to aerosol challenge with *Francisella tularensis* in mice inoculated with live vaccine candidates of varying efficacy. *PLoS One* 2010;5:e13349.
4. Nham T, Filali S, Danne C, Derbise A, Carniel E. Imaging of bubonic plague dynamics by in vivo tracking of bioluminescent *Yersinia pestis*. *PLoS One* 2012;7:e34714.
5. Sanz P, Teel LD, Alem F, Carvalho HM, Darnell SC, O'Brien AD. Detection of *Bacillus anthracis* spore germination in vivo by bioluminescence imaging. *Infect Immun* 2008;76:1036-47.
6. Green M, Choules G, Rogers D, Titball RW. Efficacy of the live attenuated *Francisella tularensis* vaccine (LVS) in a murine model of disease. *Vaccine* 2005;23:2680-6.
7. Bina XR, Miller MA, Bina JE. Construction of a bioluminescence reporter plasmid for *Francisella tularensis*. *Plasmid* 2010;64:156-61.
8. Miller MA, Stabenow JM, Parvathareddy J, et al. Visualization of murine intranasal dosing efficiency using luminescent *Francisella tularensis*: effect of instillation volume and form of anesthesia. *PLoS One* 2012;7:e31359.
9. Contag CH, Bachmann MH. Advances in in vivo bioluminescence imaging of gene expression. *Annu Rev Biomed Eng* 2002;4:235-60.
10. Shaner NC, Steinbach PA, Tsien RY. A guide to choosing fluorescent proteins. *Nat Methods* 2005;2:905-9.
11. Youn H, Hong KJ. In vivo noninvasive small animal molecular imaging. *Osong Public Health Res Perspect* 2012;3:48-59.
12. Kawasaki ES, Player A. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. *Nanomedicine* 2005;1:101-9.
13. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. *Cell* 2006;124:849-63.
14. Pechous RD, McCarthy TR, Zahrt TC. Working toward the future: insights into *Francisella tularensis* pathogenesis and vaccine development. *Microbiol Mol Biol Rev* 2009;73:684-711.
15. Hagenaaers N, Mania M, de Jong P, et al. Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine. *J Control Release* 2010;144:17-24.